NCI-MATCH / EAY131 — Targeted therapy directed by tumor genetic testing across advanced cancers (basket trial)

Phase 2 · Solid Tumors, Lymphoma, Multiple Myeloma

Population

Advanced refractory solid tumors, lymphomas, or multiple myeloma with an actionable molecular alteration.

Primary Endpoint

Objective response rate (per arm)

Rationale

NCI-MATCH tests the central premise of precision oncology — that matching a drug to a tumor's molecular alteration, regardless of cancer type, produces responses. Its many arms generate efficacy signals that guide which biomarker–drug pairs deserve larger trials.

What It Could Change

Continues to define which genomic alterations are actionable across tumor types, shaping tumor-agnostic drug development.